DXB
Asset Logo

Dimerix Limited

πŸ‡¦πŸ‡Ί ASX

🧬 BIOTECHNOLOGY

πŸ“ˆ HIGH PRICE GROWTH

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

+ 42.73%
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

19
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. The company develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The firm is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.

πŸ“ˆ Performance

Price History

+5074.74%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.34

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in DXB

19

πŸ“Š Total Capital Earnings

$24K

πŸ”ƒ Average investment frequency

48 weeks

πŸ’΅ Average investment amount

$1,241

⏰ Last time a customer invested in DXB

15 days
DXB investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

10%

100k - 150k

29%

50k - 100k

33%

Less than 50k

24%
πŸ‘Ά Age of investors

18 - 25

16%

26 - 34

37%

35 - 90

47%
πŸ™‹ Legal gender of investors

Female

37%

Male

63%

Pearlers who invest in DXB also invest in...

Vanguard Diversified High Growth Index ETF

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

4.00%

πŸ“Š Share price

$68.57 AUD

⛳️ DIVERSIFIED

🌏 GLOBAL

Find Out More

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

4.35%

πŸ“Š Share price

$104.33 AUD

⛳️ DIVERSIFIED

🧱 MATERIALS

πŸ’Έ FINANCIALS

Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is focused on developing new therapies in areas with unmet medical needs for global markets. The company is focused on developing its products, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. The company has completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease. Receptor-HIT is licensed to Excellerate Bioscience.

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

πŸ™Œ Performance (5Yr p.a)

19.63%

πŸ“Š Share price

$61.01 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡ΊπŸ‡Έ UNITED STATES

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

πŸ™Œ Performance (5Yr p.a)

82.15%

πŸ“Š Share price

$12.36 AUD

πŸ“¦ LOGISTICS

Want more shares? Try these...

πŸ“Š Share price

$0.20 AUD

Dexus Convenience Retail REIT engages in owning and management of portfolio of properties. The company is headquartered in Sydney, New South Wales and currently employs 0 full-time employees. The company went IPO on 2017-07-27. The Fund's portfolio is valued at approximately $781 million, is predominantly located on Australia's eastern seaboard and leased to Australian and international convenience retail tenants. The portfolio has a long weighted average lease expiry and contracted annual rent increases, providing a high level of income security. The Fund has a conservative approach to capital management with a target gearing range of 25-40%. The Fund consists of three registered managed investment schemes domiciled in Australia: Convenience Retail REIT No. 1, Convenience Retail REIT No. 2 and Convenience Retail REIT No. 3. The Fund's manager is Convenience Retail Management Pty Ltd.

πŸ™Œ Performance (5Yr p.a)

-2.71%

πŸ“Š Share price

$2.93 AUD

🏠 REAL ESTATE

πŸ’° HIGH DIVIDEND

Develop Global Ltd. engages in the exploration and production of mine base and precious metal resources. The firm is also involved in operations of its underground mining services division Develop Mining Services Its segments include mining services and mining and exploration. The Company’s projects include Sulphur Springs Project, Whim Creek Joint Venture, Woodlawn Project, Pioneer Dome, and Kangan Gold Project. The Sulphur Springs project is located 144 kilometers (km) to the southeast of Port Hedland and includes the Sulphur Springs and Kangaroo Caves deposits together with tenements along the 27 km Panorama Trend that contains six advanced targets that have returned intersections of commercial grade copper and zinc. The Whim Creek Joint Venture Project is located 115 km to the southwest of Port Hedland. The Woodlawn Project is a zinc-copper-lead-gold-silver project located in the Lachlan Fold belt in New South Wales, 250 km south-west of Sydney and 40 km south of Goulburn.

πŸ™Œ Performance (5Yr p.a)

362.86%

πŸ“Š Share price

$2.01 AUD

⛏️ MINING

Compare
Add to watchlist